Hageman factor (HF, Factor XII) is activated by glass, collagen, and ellagic acid, and initiates blood coagulation via the intrinsic pathway. Clq inhibits collagen-induced platelet aggregation and adherence of platelets to glass, effects attributable to the collagenlike region of Clq. We examined the actions of Clq on HF activation. Incubation of Clq with HF before addition of HF-deficient plasma extended the activated partial thromboplastin time.
Introduction
The initial step of the intrinsic pathway of thrombin formation is the activation of Hageman factor (HF,' Factor XII) by negatively charged agents, a process that can be inhibited by positively charged substances (1) . Some fractions of normal plasma are known to block the activation ofHF, but neither the identity nor mode of action of the inhibitory agents in these fractions has been clarified (2) .
Cl q, a subcomponent of the first component of complement (C1), has amino acid sequences resembling those of collagen and can inhibit collagen-induced platelet aggregation and the adherence of platelets to glass (3, 4) . Both glass and some forms of collagen activate HF (1, 5, 6) , although the effect of collagen on HF is controversial (6) (7) (8) (9) (10) (11) (12) (13) . The possibility was examined that, similar to its effect on platelets, C lq might block the activation ofHF. The experiments to be described demonstrate that Clq can inhibit the activation of HF by glass or ellagic acid. The biological significance ofthis observation is yet to be determined. 1 . Abbreviations used in this paper: BS, barbital-saline buffer, HF, Hageman factor, HPPAN, H-D-prolyl-L-phenylalanyl-L-arginine-p-nitroanilide dihydrochloride; p-NA, p-nitroaniline; P1T, partial thromboplastin time.
Plasmas. Pooled human serum and frozen citrated (acid citrate dextrose) plasma were obtained from normal human volunteers. A pool of 24 normal human plasmas was prepared from venous blood to which onefiftieth volume of 0.5 M sodium citrate buffer (pH 5.0) had been added, and stored at -70'C as previously described (14) . Human HF-deficient plasma was similarly prepared and stored. Venepuncture was performed after informed consent with the approval of the Institutional Review Board for Human Investigation, University Hospitals of Cleveland. The pooled normal plasma was arbitrarily said to contain 1 U of HF/ml, as measured in a coagulant assay.
Clq preparation. Clq was isolated from pooled human serum or frozen citrated plasma by successive chromatography upon columns of Bio-Rex 70 and Bio-Gel A5M (Bio-Rad Laboratories, Richmond, CA), using a minor modification of the method of Tenner et al. (15) in which 102 mM sodium chloride was substituted for 82 mM sodium chloride in the initial buffer used for the equilibration of the Bio-Rex 70 column (Bio-Rad Laboratories). The presence of Clq in the Clq preparation was established by Ouchterlony gel diffusion against polyclonal antihuman Clq goat antibody (Atlantic Antibodies, Scarborough, ME or Boehringer-Mannheim Biochemicals, Indianapolis, IN). The purity of Clq was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), which demonstrated homogeneous subunits of Clq. The apparent molecular weights ofthe reduced samples were 35,000, 32,000, and 28,000, as previously described (16) . Digestion of the collagenous portion ofClq was performed by a modification ofthe method of Pacques (17) by heating the Clq solution at 540C in a water bath for 10 min and then adding 0.037 ml collagenase (Clostridium histolyticum, 10 mg/ml, 689 U/mg; Cooper Biomedical, Malvern, PA). The sample was immediately removed from the water bath and freed of traces of precipitate by centrifugation at 900 g for 10 min at 20C. The sample was then precipitated at 4VC overnight by addition of(NH4)2SO4 to onethird saturation. The precipitate was collected by centrifugation, dissolved in barbital-saline buffer (BS), and dialyzed against the buffer for 1 h. A control sample was treated in a similar manner, omitting the addition of collagenase. SDS-PAGE of reduced and unreduced samples of the collagenase-treated Clq preparation exhibited homogeneous subunits; the apparent molecular weights of the subunits in the reduced sample were 25,000, 19,000, and 18,000, similar to those previously described for this digestion ( 17) .
HF preparation. Purified human HF, depleted of other detectable clotting factors (coagulant titer 2.56 U/ml; specific activity 58 U/mg protein) was prepared by a method described elsewhere (18) and stored at -700C.
Antibody preparation. Murine monoclonal anti-human Clq antibody (Genzyme, Boston, MA) was filtered through Affi-gel Blue IgG purification gel (Bio-Rad Laboratories) that had been equilibrated with 70 ml 0.02 M KH2PO4, pH 8.0; similarly prepared monoclonal antibody against von Willebrand factor (Factor VIII:vWF) was used as a control (19) . For use in these experiments the protein contents ofthe filtered samples were Blockage of the activation of HF by glass was tested by the use of various materials to coat the clotting tubes before measuring the PTT.
New 10 X 75-mm glass tubes were coated with 0.1 ml ofthe test materials, vortexed for 30 s, then rinsed three times with 10 ml BS and three times with 10 ml distilled water, and finally dried using an air jet. Then, 0.1 ml of normal pooled plasma and 0.1 ml of Centrolex-P were added to each tube and the mixture was incubated at 370C. After I min, 0.1 ml of prewarmed 0.025 M CaC12 was added, the tubes again vortexed, and the clotting time was measured.
Amidolytic assays. The amidolytic properties ofellagic acid-activated HF were tested by incubating a "generation mixture" of 0. HPPAN was added and incubation was continued for an additional hour. The reaction was stopped by addition of 0.3 ml of glacial acetic acid. The p-nitroaniline (p-NA) released from HPPAN by the generation mixture was measured by absorption at 405 nm against appropriate blanks. This assay method was used to test inhibition of the activation of HF by prior treatment of C lq versus various control substances.
Assay for protein concentrations. Protein concentrations were estimated by Lowry's method (21) .
Results
Inhibitory effect of Clq on the clot-promoting activity of HF. Addition of Clq to purified HF had a slight inhibitory effect upon the clot-promoting properties of HF, as measured by the PTT. Thus, the PTT of HF-deficient plasma, after the addition of purified HF, was 118.9 s (Table I) . Incubation of HF with 1 X 10-6 M Clq before the addition of HF-deficient plasma extended the PTT to 135.4 s. Incubation of HF with a lesser concentration of Clq (1 X 10-7 M) gave an intermediate value of 126.9 s. The prolongation of the PTT was not due to simple dilution of the HF, as the control time was measured with a volume of BS equal to that of the Clq used in these studies.
A similar result was noted when C lq was used to coat glass tubes before the addition of the normal plasma (Table II) . The PTT of normal plasma was 75.3 s when BS was used as the coating substance, but extended to 86.4 s when 1 X 10-6 M Clq was the coating substance. This PTT approached the PTT obtained when HF-deficient plasma was the coating substance, a procedure known to inhibit the activation of HF (22) . When pooled normal plasma was used as the coating substance, the PTT was 68.3 s, presumably reflecting the activation by glass of the HF present in normal plasma. A dose-response relationship was present, as decreasing the C lq concentration from 2 X 10-6 to 2 X 10`0 M resulted in a decreasing prolongation ofthe PTT, approaching the control value obtained with BS. The effect of Clq is in contrast to that of certain other proteins, as glass tubes coated with albumin or transferrin retain their clot-promoting properties (2). When Clq was added to the generation mixture after HF had been incubated with Centrolex-P in glass tubes for 2 min, and thus presumably activated, the PTT was 120.7 s, not significantly different from the 118.9 s PTT obtained when BS was substituted for Clq (Table III) . These findings suggest that Clq acts to block the activation of HF, but does not block activated HF.
Inhibition of the amidolytic property of HF by incubation with Clq. Under the conditions used, HF, after activation by ellagic acid, released 50.5 nmol p-NA/ml per h from HPPAN (Table IV) . Incubation of HF with an equal volume of 1 X 10-6 M Clq before the addition of ellagic acid reduced amidolysis to 23.5 nmol p-NA/ml per h. When Clq was added after the activation of HF by ellagic acid, 46.3 nmol p-NA/ml per h were released, a value approaching the control measurement with BS.
Clq dose-related inhibition ofHF activation. Incubation of Reversion ofClq-induced inhibition ofHF by partial digestion of Clq with collagenase. 5 X 10-6 M Clq that had been heated and partially digested by collagenase before the addition of HF and ellagic acid was not inhibitory, and led to the release of 45.6 nmol p-NA/ml per h, approximating the baseline value of42.4 nmol/ml per h obtained with the BS control (Table VIII) . Untreated Clq, or Clq that had been heated but not treated with collagenase, inhibited activation of HF as demonstrated by the release of less p-NA (17.3 nmol/ml per h and 13.8 nmol/ml per h, respectively). Some amidolysis was induced by the collagenase-digested preparation of Clq itself (8.1 nmol/ml per h p-NA). This background amidolysis presumably resulted from the presence of amidolytic activity in the preparation of collagenase, as amidolysis was not observed with untreated Clq or Clq that had only been heated. This background amidolysis resolved upon 10-fold dilution of the Clq preparations. This dilution reduced the Clq-induced inhibition of HF activation, as reflected by the higher amount ofp-NA released (30.5 nmol/ ml per h), but collagenase digestion of Clq again abolished its inhibition of HF activation, as 42.3 nmol/ml per hp-NA were released.
Discussion
The activation of HF, Factor XII, is a pivotal point in the initiation of clotting via the intrinsic pathway. Moreover, this event has relevance not only to hemostasis, but also to a legion of other biologic events that may result from activation of HF. In this report, we present evidence that Clq, the protein responsible for initiation of activation of the classical pathway of complement, may modulate the activation of the intrinsic clotting mechanism. (26) . There is evidence that a triple helix is formed between the collagen-like region of one of a pair of C chains and the corresponding regions of an AB dimer; in this manner, it is believed, three pairs of triple helices are formed (26) . Then, the association of these three pairs could give the complete hexameric structure, with six globular heads formed from the COOH-terminal halves of each chain. Clq has also been shown to be susceptible to collagenase digestion (17) . With regard to function, the globular head region mediates binding to the Fc region of immunoglobulin molecules, and the collagenous tail binds to most cells that have been studied (26) .
HF is a single chain 80,000-mol-wt plasma protein with an internal disulfide loop. Studies by Cochrane and Revak et al. (27) demonstrated that the adsorption of HF from diluted normal human plasma to negatively charged glass surfaces brought about scission of the molecule. HF was first cleaved at the internal disulfide loop into a two-chain species and later into several fragments, notably a 52,000-mol-wt amino-terminal fragment and a 28,000-mol-wt carboxy-terminal fragment. The enzymatic properties of HF have been localized to the carboxy-terminal fragment (28) .
HF is a plasma proenzyme that, when activated, can initiate clotting via both the intrinsic and extrinsic pathways of thrombin generation, and additionally brings about reactions that lead to the generation of kinins, plasmin, and angiotensin, and to the activation of certain components of the complement pathway (29) (30) (31) (32) . Activation of HF can be brought about by its exposure to negatively charged agents such as glass, kaolin (22) , ellagic acid (33), a serine protease that is present in the microsomal fraction of endothelial cells (34) , a combination of collagen and some other unidentified basement membrane components (27) , and some but not all preparations of collagen (5) (6) (7) (8) (9) (10) (11) (12) (13) . HF that has been activated during the "contact phase" of blood coagulation is inhibited by CI inactivator (35) and antithrombin III (36) . Plasma contains undefined material that inhibits the adsorption of HF to glass and may also interfere with the surface activation of the proenzyme in the initiation of physiological blood coagulation (2) . In this regard, 132-glycoprotein I, which, like collagen, is rich in proline residues, has recently been shown to inhibit contact activation of the intrinsic coagulation pathway (37) .
Clq inhibits collagen-induced platelet aggregation (3) and the adherence of platelets to glass surfaces (4). The structural similarity of collagen and Clq led to the suggestion that Clq may occupy a collagen-receptor site on platelets, and thus inhibit aggregation. It has also been demonstrated that a murine monoclonal antibody raised against the Raji cell Clq receptor binds to human platelets and abolishes collagen-induced platelet aggregation (38) . Clq also may form complexes with plasma fibronectin but this interaction does not alter Clq-mediated inhibition of collagen-induced platelet aggregation (39) . The effects of glass and collagen on platelets, as altered by Clq, led us to consider the possibility that Clq could alter the effects of glass and ellagic acid on HF.
These studies demonstrate that Clq inhibits the clot-promoting and amidolytic properties of HF. Clq blocked the activating effect of glass and ellagic acid on HF but did not inhibit activated HF. The marked resemblance of the fibrillar portion of Clq to collagen and the reported activation of HF by some (but not all) preparations ofcollagen suggest that Clq may block a site on glass or ellagic acid that HF requires for activation. Alternately, Clq may block a site on HF itself that is required for activation. The precise mechanism of inhibition by Clq, however, remains to be clarified.
A dose-response relationship between the amount of Clq present and the degree of prolongation of the PTT, as well as inhibition of amidolysis, was noted in replicate experiments.
The reversion of the Clq inhibition of the activation of HF by prior incubation with murine monoclonal anti-human C lq antibody substantiates the conclusion that it is Clq itself that is responsible for the alteration of HF activation. That collagenase treatment of Clq also destroyed its ability to inhibit HF activation suggests that it is the collagenous, fibrillar portion of the Clq molecule that is responsible for the inhibitory effect.
HF has previously been demonstrated to have significant effects on the activation of certain components of the complement pathway, either directly or via formation of kallikrein or plasmin (30, 31). The inhibitory effect ofClq on the activation of HF demonstrated here suggests a method by which HF activation can be regulated by the complement pathway, and thus is a possible feedback inhibitory mechanism of the clotting cascade.
Clq has a molecular weight of 400,000 and has a serum concentration of 70 ,g/ml or -2 X io-7 M. The plasma concentration of HF is 15-45 gg/ml or -4 X 10-7 M. Demonstration of the inhibitory effect of Clq on activation of HF at concentrations as low as 2 X 10-10 M (Table II) suggests that this phenomenon could be relevant at physiologic concentrations.
The complement system and the intrinsic clotting cascade have remarkable similarities, including the requirement for initial binding to an activator to initiate a reaction sequence that then proceeds to completion. The reactions are carefully modulated or amplified, depending on the circumstances, by a complex network of control mechanisms. Ci inactivator functions as a major regulatory molecule in both systems (30). It is thus perhaps not surprising that Clq, the initiating molecule in the cascade comprising the classical pathway of complement, also appears to have a potential regulatory role in the intrinsic clotting mechanism.
